1. Indications and Usage
\nProgressive Fibrosing Interstitial Lung Diseases (PF-ILD):
\nInvestigational indication for the treatment of adult patients with progressive fibrosing interstitial lung diseases.
\nAcute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF):
\nInvestigational indication for the prevention or treatment of acute exacerbations in patients with IPF.
\n2. Dosage and Administration
\nRecommended Dosage:
\nDose: 12 mg orally twice daily.
\nAdministration: Take with food to reduce gastrointestinal adverse reactions. Swallow tablets whole.
\nMissed Dose:
\nIf a dose is missed, it may be taken as soon as possible with food. If it is close to the next scheduled dose, skip the missed dose.
\n3. Mechanism of Action
\nPDE4B Inhibition:
\nNerandomilast is a potent and selective inhibitor of phosphodiesterase 4B (PDE4B).
\nPhysiological Effect:
\nBy inhibiting PDE4B, it increases intracellular cyclic AMP (cAMP) levels, thereby suppressing inflammation and fibrotic processes without causing emesis (nausea\/vomiting), which is a common side effect of non-selective PDE4 inhibitors.
\n4. Safety and Warnings
\nGastrointestinal Disorders:
\nNausea and diarrhea have been reported. Taking the medication with food is recommended to mitigate these risks.
\nEmbryo-Fetal Toxicity:
\nMay cause fetal harm. Females of reproductive potential must use effective contraception during treatment and for at least 1 week after the final dose.
\nPsychiatric Disorders:
\nAs with other PDE4 inhibitors, monitor for psychiatric symptoms such as depression or anxiety, although the risk is considered lower with this selective agent.
\n5. Adverse Reactions
\nMost Common:
\nDiarrhea, nausea, vomiting, and headache.
\n6. Drug Interactions
\nCYP450 Interaction:
\nNerandomilast is primarily metabolized by CYP3A4. Avoid concomitant use with strong CYP3A inhibitors or inducers.
\nTransporter Substrates:
\nCaution is advised when used with P-gp or BCRP substrates.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Nerandomilast.
\nStorage:
\nStore at room temperature. Keep in original package to protect from moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u00a0 \u535a\u4f18\u7ef4 \u00ae(Jascayd\u00ae )
\nGeneric Name: Nerandomilast
\nStrength: 9 mg per tablet, 30 tablets per box
\nManufacturer: Boehringer Ingelheim Pharma GmbH & Co. KG
\nMarketing Authorization Holder: Boehringer Ingelheim International GmbH
\nApproval Date in China: October 22, 2025
\nRegistration Number: HJ20250125
\nStorage: Store in the original container, protect from light, store at 20\u2103~25\u2103, short-term temperature fluctuation between 15\u2103~30\u2103 is allowed, keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Nerandomilast (Jascayd\uff09<\/p>\n","protected":false},"featured_media":3352,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[88],"product_cat":[27],"product_tag":[],"class_list":["post-3351","product","type-product","status-publish","has-post-thumbnail","product_brand-boehringer","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n